Acute Leukemia, Multiple Myeloma, Squamous Cell Carcinoma, Pleural Mesothelioma, Pancreatic Cancer, Bladder Cancer, Ovarian Cancer, Melanoma, Pediatric Acute Lymphoblastic Leukemia, Chronic Leukemia, Myeloproliferative Disorders, Myelodysplastic Disorders
Conditions
Brief summary
This is a multicenter, experimental preclinical study conducted on primary samples from patients diagnosed with hematological or solid neoplasms defined as high risk. The study will be prospective, based on the consecutive enrollment of eligible patients at each participating institution.
Detailed description
This pre-clinical, experimental study will involve primary samples from patients diagnosed with haematological or solid neoplasms defined as high-risk. It will be prospective, based on consecutive enrolment of eligible patients at each participating institution. Patients will be enrolled based on their biological and clinical characteristics at the time of diagnosis. This will include patients with metastatic disease, as well as those with recurrent or refractory disease, particularly where the therapeutic indication is not supported by internationally recognised guidelines.
Interventions
BIOLOGICALFunctional tests
Functional analyses will be performed on primary sample from each enrolled patient. Malignant cells are cultered and incubated with a specific library of drugs (300 drugs) at four different concentrations for 72 hours.
OTHERMulti-omics analyses
Our scientific approach is based on various investigations, including radiomics, digital pathology, immune profiling, bulk transcriptomics, single-cell resolution, single-cell transcriptomics, phosphoproteomics, functional immunoprofiling, and inflammasome analysis, NGS (Next Generation Sequencing analysis).
GENETICCytogenetics/ FISH
Individual biopsy samples will be evaluated in a pipeline that includes established diagnostic elements, e.g., cytogenetics and FISH.
Sponsors
Azienda Ospedaliero-Universitaria di Parma
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
BASIC_SCIENCE
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
1 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patients aged one year and over who are referred to the centres involved in the protocol (Azienda Ospedaliero-Universitaria di Parma, University of Parma, University of Perugia and Azienda Ospedali Riuniti Villa Sofia-Cervello of Palermo). * Patients with an established diagnosis of haematological or solid organ malignancy, including haematological or solid malignancies characteristic of the paediatric age group. * Patients diagnosed with relapsed, refractory and/or metastatic haematological or solid malignancy. Patients may be enrolled regardless of the extent and type of previous therapy. Patients may also be enrolled if they are undergoing active treatment at the time of evaluation. * Patients must have the capacity to understand the investigative nature of the study and provide informed consent in writing. For patients under the age of 12 years, consent will be provided by the parent/legal guardian according to international guidelines. For patients aged 12 to 17 years, consent will be provided by the patient and the parent/legal guardian according to the mature minor principle.
Exclusion criteria
* Patients younger than 1 year old * Patients with active, uncontrolled infections
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Evaluation of the rate of change in therapeutic indication of disease from standard-of-care. | At baseline |
Secondary
| Measure | Time frame |
|---|---|
| Evaluation of the possible use of the IT-TCP platform on the clinical level | At baseline |
| Creation of an IT platform to store and manage the data generated | At baseline |
Countries
Italy
Contacts
CONTACTGiovanni Roti, Associate Professor
Outcome results
None listed